{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:30:53Z","timestamp":1772159453270,"version":"3.50.1"},"reference-count":42,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bernola-Vallribera Foundation, Sant Josep 2018","award":["CIR2018\/036"],"award-info":[{"award-number":["CIR2018\/036"]}]},{"name":"Taul\u00ed Research and Innovation 2018","award":["CIR2018\/036"],"award-info":[{"award-number":["CIR2018\/036"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>We characterized the fatty acid profiles in the erythrocyte membrane of pediatric patients with cystic fibrosis (CF) receiving highly concentrated docosahexaenoic acid (DHA) supplementation (Tridocosahexanoin-AOX\u00ae 70%) at 50 mg\/kg\/day (n = 11) or matching placebo (n = 11) for 12 months. The mean age was 11.7 years. The DHA group showed a statistically significant improvement in n-3 polyunsaturated fatty acids (PUFAs), which was observed as early as 6 months and further increased at 12 months. Among the n-3 PUFAs, there was a significant increase in DHA and eicosapentaenoic acid (EPA). Additionally, a statistically significant decrease in n-6 PUFAs was found, primarily due to a decrease in arachidonic acid (AA) levels and elongase 5 activity. However, we did not observe any changes in linoleic acid levels. The long-term administration of DHA over one year was safe and well tolerated. In summary, the administration of a high-rich DHA supplement at a dose of 50 mg\/kg\/day for one year can correct erythrocyte AA\/DHA imbalance and reduce fatty acid inflammatory markers. However, it is important to note that essential fatty acid alterations cannot be fully normalized with this treatment. These data provide timely information of essential fatty acid profile for future comparative research.<\/jats:p>","DOI":"10.3390\/jcm12113704","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T16:17:33Z","timestamp":1685204253000},"page":"3704","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Changes of Erythrocyte Fatty Acids after Supplementation with Highly Concentrated Docosahexaenoic Acid (DHA) in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial"],"prefix":"10.3390","volume":"12","author":[{"given":"Roser","family":"Ayats-Vidal","sequence":"first","affiliation":[{"name":"Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Bosque-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-9387","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Cordobilla","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, E-08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Asensio-De la Cruz","sequence":"additional","affiliation":[{"name":"Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, Parc Taul\u00ed 1, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-3052","authenticated-orcid":false,"given":"Jes\u00fas","family":"Castro-Marrero","sequence":"additional","affiliation":[{"name":"ME\/CFS Research Unit, Division of Rheumatology, Vall d\u2019Hebron Research Institute, Universitat Aut\u00f2noma de Barcelona, E-08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"L\u00f3pez-Rico","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Institut d\u2019Investigaci\u00f3 I Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Parc Taul\u00ed Hospital Universitari, Universitat Aut\u00f2noma de Barcelona, E-08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6356-0836","authenticated-orcid":false,"given":"Joan Carles","family":"Domingo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, E-08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hanssens, L.S., Duchateau, J., and Casimir, G.J. (2021). CFTR Protein: Not just a chloride channel?. Cells, 10.","DOI":"10.3390\/cells10112844"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"881470","DOI":"10.3389\/fped.2022.881470","article-title":"Translational research in cystic fibrosis: From bench to beside","volume":"10","author":"Garcia","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1203\/00006450-198501000-00028","article-title":"Fatty acid abnormalities in cystic fibrosis","volume":"19","author":"Farrell","year":"1985","journal-title":"Pediatr. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jcf.2006.01.004","article-title":"Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis","volume":"5","author":"Jumpsen","year":"2006","journal-title":"J. Cyst. Fibros."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJMoa021218","article-title":"Association of cystic fibrosis with abnormalities in fatty acid metabolism","volume":"350","author":"Freedman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s004310050750","article-title":"Essential fatty acid deficiency in well nourished young cystic fibrosis patients","volume":"156","author":"Roulet","year":"1997","journal-title":"Eur. J. Pediatr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.plefa.2010.07.002","article-title":"Fatty acid metabolism in cystic fibrosis","volume":"83","author":"Strandvik","year":"2010","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12011-007-0041-9","article-title":"Serum zinc concentrations in cystic fibrosis patients aged above 4 years: A cross-sectional evaluation","volume":"119","author":"Robberecht","year":"2007","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(78)91620-3","article-title":"Fatty-acid composition of serum-lecithins in cystic-fibrosis patients without steatorrhoea","volume":"2","author":"Galabert","year":"1978","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0140-6736(77)90359-2","article-title":"Abnormal fatty-acid composition of plasma-lipids in cystic fibrosis. A primary or a secondary defect?","volume":"2","author":"Hubbard","year":"1977","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1203\/00006450-198009000-00015","article-title":"Long chain non-esterified fatty acid pattern in plasma of cystic fibrosis patients and their parents","volume":"14","author":"Rogiers","year":"1980","journal-title":"Pediatr. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Shrestha, N., McCarron, A., Rout-Pitt, N., Donnelley, M., Parsons, D.W., and Hryciw, D.H. (2022). Essential fatty acid deficiency in cystic fibrosis disease progression: Role of genotype and sex. Nutrients, 14.","DOI":"10.3390\/nu14214666"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16083","DOI":"10.3390\/ijms150916083","article-title":"Abnormal unsaturated fatty acid metabolism in cystic fibrosis: Biochemical mechanisms and clinical implications","volume":"15","author":"Seegmiller","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1194\/jlr.M700388-JLR200","article-title":"Al-Turkmani MR, Savaille JE, Alturkmani R, Katrangi W, Cluette-Brown JE; et al. Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism","volume":"49","author":"Andersson","year":"2008","journal-title":"J. Lipid. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1203\/00006450-198408000-00005","article-title":"Abnormal fatty acid turnover in the phospholipids of the red blood cell membranes of cystic fibrosis patients (in vitro study)","volume":"18","author":"Rogiers","year":"1984","journal-title":"Pediatr. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ajcn\/54.6.1029","article-title":"Essential fatty acid status and fluidity of plasma phospholipids in cystic fibrosis infants","volume":"54","author":"Johnson","year":"1991","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0009-8981(80)90098-4","article-title":"Altered phospholipid composition and changed fatty acid pattern of the various phospholipid fractions of red cell membranes of cystic fibrosis children with pancreatic insufficiency","volume":"105","author":"Rogiers","year":"1980","journal-title":"Clin. Chim. Acta."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/apa.1989.78.s363.58","article-title":"Relation between essential fatty acid metabolism and gastrointestinal symptoms in cystic fibrosis","volume":"363","author":"Strandvik","year":"1989","journal-title":"Acta Paediatr. Scand. Suppl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365528809090205","article-title":"Relation between defective regulation of arachidonic acid release and symptoms in cystic fibrosis","volume":"143","author":"Strandvik","year":"1988","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13995","DOI":"10.1073\/pnas.96.24.13995","article-title":"A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-\/-) mice","volume":"96","author":"Freedman","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2008-0279OC","article-title":"Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide","volume":"41","author":"Guilbault","year":"2009","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jnutbio.2014.09.001","article-title":"Polyunsaturated fatty acid supplementation reverses cystic fibrosis-related fatty acid abnormalities in CFTR-\/- mice by suppressing fatty acid desaturases","volume":"26","author":"Njoroge","year":"2015","journal-title":"J. Nutr. Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000177734","article-title":"Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis","volume":"36","author":"Christophe","year":"1992","journal-title":"Ann. Nutr. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/ajcn\/62.6.1268","article-title":"Fatty acid pool size in plasma lipoprotein fractions of cystic fibrosis patients","volume":"62","author":"Clandinin","year":"1995","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jnutbio.2018.09.026","article-title":"A comprehensive evaluation of omega-3 fatty acid supplementation in cystic fibrosis patients using lipidomics","volume":"63","author":"Pastor","year":"2019","journal-title":"J. Nutr. Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nut.2005.05.006","article-title":"Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: A randomized, controlled study","volume":"22","author":"Powers","year":"2006","journal-title":"Nutrition"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102186","DOI":"10.1016\/j.plefa.2020.102186","article-title":"Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: A randomized, multi-center, double-blind, placebo-controlled trial","volume":"162","author":"Garriga","year":"2020","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.plefa.2012.10.002","article-title":"A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis","volume":"88","author":"Alicandro","year":"2013","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_30","first-page":"10:938","article-title":"Arachidonic acid and docosahexaenoic acid metabolites in the airways of adults with cystic fibrosis: Effect of docosahexaenoic acid supplementation","volume":"23","author":"Teopompi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcf.2004.11.001","article-title":"Docosahexaenoic acid trials in cystic fibrosis: A review of the rationale behind the clinical trials","volume":"4","author":"Robberecht","year":"2005","journal-title":"J. Cyst. Fibros"},{"key":"ref_32","first-page":"CD002201","article-title":"Omega-3 fatty acid supplementation for cystic fibrosis","volume":"4","author":"Watson","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_33","unstructured":"Brudy Technology SL. (2014). Use of DHA for Treating a Pathology Associated with Cellular Oxidative Damage. (EP 1962825 B1), European Patent."},{"key":"ref_34","first-page":"5932","article-title":"Docosahexaenoic acid improves endogenous antioxidant defense in ARPE-19 cells","volume":"49","author":"Gasso","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-2275(20)38861-1","article-title":"Direct transesterification of all classes of lipids in a one-step reaction","volume":"27","author":"Lepage","year":"1986","journal-title":"J. Lipid. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1203\/00006450-198809000-00016","article-title":"Supplemental calories improve essential fatty acid deficiency in cystic fibrosis patients","volume":"24","author":"Parsons","year":"1988","journal-title":"Pediatr. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103038","DOI":"10.1016\/j.ebiom.2020.103038","article-title":"Glued in lipids: Lipointoxication in cystic fibrosis","volume":"61","author":"Vandebrouck","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1467S","DOI":"10.1093\/ajcn\/83.6.1467S","article-title":"Distribution, interconversion, and dose response of n-3 fatty acids in humans","volume":"83","author":"Arterburn","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.plefa.2007.12.005","article-title":"Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients","volume":"78","author":"Devos","year":"2008","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.plefa.2007.05.003","article-title":"Fatty acid composition of plasma, blood cells and whole blood: Relevance for the assessment of the fatty acid status in humans","volume":"76","author":"Eligini","year":"2007","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/ajcn\/86.1.74","article-title":"Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women","volume":"86","author":"Sun","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.chemphyslip.2014.09.006","article-title":"Associations between erythrocyte membrane fatty acid compositions and insulin resistance in obese adolescents","volume":"184","author":"Gunes","year":"2014","journal-title":"Chem. Phys. Lipids"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3704\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:43:08Z","timestamp":1760125388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["jcm12113704"],"URL":"https:\/\/doi.org\/10.3390\/jcm12113704","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]}}}